tiprankstipranks
COSMO Pharmaceuticals N.V. (DE:C43)
FRANKFURT:C43

COSMO Pharmaceuticals N.V. (C43) Price & Analysis

4 Followers

C43 Stock Chart & Stats

€105.00
-€1.00(-1.46%)
At close: 4:00 PM EST
€105.00
-€1.00(-1.46%)

Bulls Say, Bears Say

Bulls Say
Strong Balance SheetVery low leverage and substantial equity provide durable financial flexibility. A conservative balance sheet (~482M equity, minimal debt) lets management fund R&D, support commercialization, absorb cyclical revenue swings and pursue partnerships without immediate financing stress.
Specialized Gastroenterology FranchiseA focused product set in gastroenterology and endoscopy creates a differentiated, specialist franchise. Proprietary therapies, devices and licensing/commercialization capabilities align with structural demand from clinicians and endoscopy centers, supporting durable customer relationships and recurring revenue potential.
High-profit Potential In Good YearsThe company has demonstrated it can generate very high margins and substantial cash when commercial conditions align. Exceptional 2024 profitability and cash generation show scalable economics and indicate meaningful upside if product mix, pricing or licensing activity normalize toward that performance.
Bears Say
Revenue & Earnings VolatilitySharp swings between very strong and weak years undermine visibility and long-term planning. Revenue and margin volatility complicate forecasting, hinders consistent reinvestment in commercialization and R&D, and raises execution risk for licensing or partnership strategies over the medium term.
Cash Flow DeteriorationA swing from large positive cash generation to cash burn materially reduces internal funding capacity. Sustained negative OCF/FCF would force use of reserves or external financing, constraining long-term investments in product development, commercialization and strategic initiatives.
Inconsistent Returns To Capital (ROE Reversal)ROE flipping negative after an exceptional year signals inconsistent return generation and earnings quality issues. This uneven profitability makes capital allocation harder, can weaken investor confidence and may limit the company's ability to fund growth without dilutive or costly financing.

COSMO Pharmaceuticals N.V. News

C43 FAQ

What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €57.50 and its highest was €141.00 in the past 12 months.
    What is COSMO Pharmaceuticals N.V.’s market cap?
    COSMO Pharmaceuticals N.V.’s market cap is €1.28B.
      When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
      COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2026 which is in 37 days.
        How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
        COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -€0.1 earnings per share for the quarter, missing the consensus estimate of €0.2 by -€0.3.
          Is COSMO Pharmaceuticals N.V. overvalued?
          According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does COSMO Pharmaceuticals N.V. pay dividends?
            COSMO Pharmaceuticals N.V. does not currently pay dividends.
            What is COSMO Pharmaceuticals N.V.’s EPS estimate?
            COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
              How many shares outstanding does COSMO Pharmaceuticals N.V. have?
              COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
                What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
                COSMO Pharmaceuticals N.V. reported an EPS of -€0.1 in its last earnings report, missing expectations of €0.2. Following the earnings report the stock price went down -9.483%.
                  Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
                  Currently, no hedge funds are holding shares in DE:C43
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Company Description

                    COSMO Pharmaceuticals N.V.

                    Cosmo Pharmaceuticals N.V. operates as a specialized biopharmaceutical firm, primarily focused on the global development and commercialization of treatments and diagnostic tools within the gastroenterology and endoscopy fields. Its product lineup includes oral tablet formulations like Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, which are prescribed to achieve remission in cases of active, mild to moderate ulcerative colitis. The company also pioneers innovative diagnostic solutions such as GI Genius, an artificial intelligence-driven system designed to enhance the detection of colorectal polyps, and Methylene Blue MMX, a diagnostic drug that improves the visibility of pre-cancerous and cancerous colorectal lesions during colonoscopy procedures. For gastrointestinal endoscopic interventions, Cosmo provides Eleview, an injectable composition used to facilitate the submucosal lift of polyps, adenomas, early-stage cancers, and other mucosal lesions. Beyond its core GI offerings, the company's portfolio extends to Aemcolo/Relafalk, a pharmaceutical indicated for traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth. In the dermatological space, it offers Winlevi, an androgen receptor inhibitor for the treatment of acne vulgaris. Further developments encompass Clascoterone, another androgen receptor inhibitor targeting androgenetic alopecia on the scalp; Rifamycin for irritable bowel syndrome with diarrhea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent employed for procedural sedation; CB-03-10, an oral androgen receptor antagonist under investigation for solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a unique single-use enema formulation. Cosmo Pharmaceuticals N.V. has established licensing agreements with partners including RedHill Biopharma Ltd. and Acacia Pharma Group plc. The company was founded in 1997 and its corporate headquarters are located in Dublin, Ireland.

                    COSMO Pharmaceuticals N.V. (C43) Earnings & Revenues

                    C43 Stock 12 Month Forecast

                    Average Price Target

                    €155.53
                    ▲(48.13% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"55":"€55","174":"€174","84.75":"€84.8","114.5":"€114.5","144.25":"€144.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":173.61999999999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€173.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":155.53458333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€155.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.06625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€141.07</span>\n  </div></div>","useHTML":true}}],"tickPositions":[55,84.75,114.5,144.25,174],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.6,91.44769230769231,98.2953846153846,105.14307692307692,111.99076923076922,118.83846153846153,125.68615384615384,132.53384615384613,139.38153846153844,146.22923076923075,153.07692307692307,159.92461538461538,166.77230769230766,{"y":173.61999999999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.6,90.0565064102564,95.51301282051281,100.96951923076922,106.42602564102563,111.88253205128204,117.33903846153845,122.79554487179487,128.25205128205127,133.7085576923077,139.1650641025641,144.6215705128205,150.07807692307694,{"y":155.53458333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,84.6,88.94355769230769,93.28711538461538,97.63067307692307,101.97423076923076,106.31778846153846,110.66134615384615,115.00490384615384,119.34846153846154,123.69201923076923,128.03557692307692,132.3791346153846,136.7226923076923,{"y":141.06625,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.711,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.221,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.013,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.034,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.992,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.627,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.38,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.535,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.6,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Basilea Pharmaceutica
                    Kuros Biosciences
                    medmix AG
                    Medartis Holding AG

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks